SynGen
At SynGen Inc. we develop advanced cell separation tools and accessories, applying innovative design to aid regenerative medicine workflows.
We design and manufacture products that focus on improving recovery of target cells, depletion of contaminating cells, high efficiency and operator ease of use.
The result is the production of enhanced cell therapy products in less time.
SynGen Key Features
- Innovative devices designed for separation and isolation of therapeutic cells
- High cell yields
- Consistent and reliable performance
- Electronic documentation of critical process step
The SynGen Management Team includes:
- William Gerber , President and CEO
- Philip H. Coelho, CTO and Co-Founder
- Chuck Novak, Vice President and Chief Financial Officer
- Frank Pascale, President, Cord Blood SBU
- David Hodl, President, Cell Processing SBU
- Paul Hoseit, Senior Vice President, Research and Development
- Barbara Fullmer, Senior Director of Quality Affairs
SynGen Mission Statement:
SynGen Inc. advances the field of regenerative medicine by providing researchers and clinicians with innovative, robust systems that improve the recovery and purity of cells.
SynGen Quality Statement:
SynGen Inc. provides safe and effective products and services on a timely basis that meet or exceed the customers’ requirements, upholding compliance with all regulations, and assuring the continual effectiveness and improvement of SynGen’s Quality System.